
Oncotarget
Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Oncotarget is now indexed by MEDLINE, PubMed and PMC/PubMed.
Read about the Oncotarget Scientific Integrity Process: https://www.oncotarget.com/scientific_integrity/
Latest episodes

Nov 13, 2023 • 2min
C/EBPβ Helps MYB Maintain the Oncogenic Program of AML Cells
Karl-Heinz Klempnauer, a researcher, discusses recent studies on the role of MYB in AML cells. MYB is a key regulator of self-renewal in AML cells, and it is also important in the development and maintenance of leukemia in humans. The podcast explores the cooperative effect of C/EBPβ and MYB in maintaining leukemic cells and the potential therapeutic applications of this knowledge.

Nov 8, 2023 • 3min
Combined Inhibition of SHP2 and Mutated RTKs Prevent Adaptive Resistance in Leukemia
In the podcast, researchers discuss potential leukemia therapies to prevent adaptive resistance. They explore the need for more potent inhibitors and combination therapies in treating leukemia.

Nov 6, 2023 • 2min
The Role of HER2 Mutant Alleles in Breast Cancer
Guests Rashi Kalra, Bora Lim, Matthew J. Ellis, and Shyam M. Kavuri discuss the role of HER2 mutant alleles in breast cancer. They explore the effects of these alleles on therapeutic response, metastatic propensity, and patient outcomes in different types of breast cancer. They also discuss the potential of the pan-HER inhibitor poziotinib as a therapeutic agent.

Nov 2, 2023 • 5min
p53’s Protective Role in Extrahepatic Biliary Precancerous Lesions
Explore the genetic factors contributing to extrahepatic biliary cancer, including the mutation of Kras and p53. Researchers discuss their study on the role of p53 in preventing the development of precancerous lesions. Learn about the protective function of p53 and its implications for biliary cancer progression.

Nov 1, 2023 • 3min
FAAH Inhibition Ameliorates Murine Breast Cancer
Researchers discuss the therapeutic potential of FAAH inhibition and endocannabinoids for breast cancer treatment, specifically exploring the effects on cancer cell viability and apoptosis.

Oct 30, 2023 • 4min
Neutrophil PAD4 in Cancer, Beyond Promoting NETosis
Laura Ga, a researcher studying the function of Neutrophil PAD4 in cancer beyond promoting NETosis, discusses the role of myeloid-derived suppressor cells (MDSC) in cancer growth. She explains how tumor-infiltrating PMN-MDSCs suppress immune responses and the potential of targeting PAD4 for inhibiting tumor progression.

Oct 25, 2023 • 3min
Genetic Modifiers of p53 and Their Potential in Breast Cancer Therapies
Guest Prabin Dhangada Majhi discusses the role of genetic modifiers of p53 in breast cancer therapies. They highlight the prevalence of TP53 mutations in tumors, its significance as a barrier to oncogenic transformation, and the vulnerability of breast epithelium. Also mentioned are the potential contributions of over 300 polymorphisms in breast cancer risk.

Oct 23, 2023 • 3min
Apoptotic Cells May Drive Cell Death in Hair Follicles During Regression Cycle
This podcast explores the role of apoptotic cells in driving cell death in hair follicles during their regression cycle. The researchers conducted intervital microscopic studies on live mice and discovered that the elimination of epithelial cells involves super basal cell differentiation and basal cell apoptosis. They proposed a mathematical model to describe the regression cycle and suggest that apoptotic cells induce apoptosis in neighboring cells.

Oct 20, 2023 • 5min
How a Metabolic Enzyme Can Trigger Cell Death in Liver Cancer Cells
Researchers discuss the role of metabolic enzyme GLS2 in regulating cell death (ferroptosis) in liver cancer cells, highlighting the potential for targeted therapies and immunotherapies. GLS2's clinical relevance and therapeutic potential for hepatocellular carcinoma are explored.

Oct 19, 2023 • 3min
GLS2 Shapes Ferroptosis in Hepatocellular Carcinoma
Researchers from Columbia University discuss the role of GLS2 in inducing ferroptosis and its potential therapeutic implications for liver diseases. They explore its relationship with p53 and SLC7A11 and highlight a recent study validating GLS2's promotion of ferroptosis in mouse models.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.